Endometrial Cancer Pipeline Market Research H2 2015 Report

02 Mar, 2016, 21:00 ET from ReportsnReports

PUNE, India, March 3, 2016 /PRNewswire/ --

A market research report titled "Endometrial Cancer - Pipeline Review, H2 2015" provides an overview of the Endometrial Cancer's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Company Profiles discussed in this report includes Ability Pharma, SL, Acceleron Pharma, Inc., Advenchen Laboratories, LLC, Aeterna Zentaris Inc., Arno Therapeutics, Inc., ArQule, Inc., AstraZeneca Plc, AVEO Pharmaceuticals, Inc., BeiGene(Beijing) Co.,Ltd, Boehringer Ingelheim GmbH, Cellceutix Corporation, Critical Outcome Technologies Inc., Eisai Co., Ltd., Eli Lilly and Company, Esperance Pharmaceuticals, Inc., Exelixis, Inc., Galena Biopharma, Inc., Genmab A/S, GlaxoSmithKline Plc, Gradalis Inc., ImmunoGen, Inc., Incyte Corporation, Karyopharm Therapeutics, Inc., Medivation, Inc., Merck & Co., Inc., Merck KGaA, Millennium Pharmaceuticals, Inc., Novartis AG, OncoHoldings, Inc., Oncothyreon Inc., Otsuka Holdings Co., Ltd., Pharma Mar, S.A., Pharmsynthez, Puma Biotechnology, Inc., Sanofi, Scancell Holdings Plc and Shenogen Pharma Group Ltd. Complete report on H2 2015 pipeline review of Endometrial Cancer with 57 market data tables and 16 figures, spread across 280 pages is available at http://www.reportsnreports.com/reports/453485-endometrial-cancer-pipeline-review-h2-2015.html .

Drugs Profiles discussed in this report includes Pb-TCMC-Trastuzumab, ABTL-0812, AEZS-125, AL-3818, ARQ-092, AV-203, AZD-2014, AZD-5363, BGB-283, buparlisib hydrochloride, cabozantinib s-malate, cancer vaccine, Cell Therapy for Ovarian and Endometrial Cancer, Cell Therapy to Target HER-2 for Oncology, CLR-457, COTI-2, cridanimod, dalantercept, EP-200, epacadostat, everolimus, GALE-301, GSK-2636771, HO-3867, HuMax-TF-ADC, INCB-54828, KM-3174, lenvatinib, lurbinectedin, LY-3023414, mirvetuximab soravtansine, MK-2206, Modi-1, Monoclonal Antibody to Inhibit L1CAM for Ovarian and Endometrial Cancer, neratinib, nintedanib, onapristone ER, ONCO-101, ONT-10, OPB-111001, Peptides to Inhibit GnRH II Receptor for Oncology, pimasertib hydrochloride + voxtalisib, sapanisertib, SAR-408701, selinexor, Small Molecules to Inhibit Skp2 for Endometrial Cancer and Melanoma, SNG-1153, SP-2509, talazoparib, trametinib dimethyl sulfoxide + uprosertib, X-480 and zoptarelin doxorubicin.

Order a Purchase copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=453485 .

This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects.

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Endometrial Cancer. The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities and also key players involved in the therapeutics development for Endometrial Cancer and enlists all their major and minor projects summarizing all the dormant and discontinued pipeline projects. A review of the Endometrial Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources, pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Endometrial Cancer pipeline on the basis of target, MoA, route of administration and molecule type and latest news and deals relating related to pipeline products.

Another newly published market research report titled on Hepatocellular Carcinoma - Pipeline Review, H2 2015 provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Hepatocellular Carcinoma Pipeline market research report of 369 pages is available at http://www.reportsnreports.com/reports/468279-hepatocellular-carcinoma-pipeline-review-h2-2015.html .

About Us:   

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
sales@reportsandreports.com

Connect With Us on:
Facebook: https://www.facebook.com/ReportsnReports/
LinkedIn: https://www.linkedin.com/company/reportsnreports
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
RSS/Feeds:  http: //http://www.reportsnreports.com/feed/l-latestreports.xml


SOURCE ReportsnReports